Printer Friendly

Enzyvant Begins Rolling Submission of BLA for Single Administration cDGA Treatment.

M2 PHARMA-July 13, 2018-Enzyvant Begins Rolling Submission of BLA for Single Administration cDGA Treatment

(C)2018 M2 COMMUNICATIONS

- Basel, Switzerland- and Cambridge, Massachusetts-based biopharmaceutical company Enzyvant has initiated its rolling submission of a biologics license application (BLA) for RVT-802 to the US FDA, the company said.

RVT-802 is an investigational, single administration, tissue-based regenerative therapy designed to treat the primary immune deficiency resulting from congenital athymia associated with complete DiGeorge Anomaly (cDGA) which is uniformly fatal if untreated, with death typically occurring in the first 24 months of life due to susceptibility to infection.

As part of the FDA's commitment to expedite therapeutics that aim to address high unmet medical needs, the agency has agreed to a rolling BLA submission process for RVT-802. RVT-802 has been designated as breakthrough therapy, regenerative medicine advanced therapy, rare pediatric disease, and orphan drug by the FDA.

Enzyvant is focused on developing innovative treatments for patients with rare diseases. The company is currently working on RVT-802 for complete DiGeorge Anomaly and RVT-801, an investigational enzyme replacement therapy for the treatment of Farber disease.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 13, 2018
Words:190
Previous Article:Cellect Secures Supply of Key Component in Agreement with Swiss Biotech.
Next Article:Bio-Techne Uses CRISPR Gene Editing System to Validate Antibodies in KO Cell Lines.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters